Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 11, 2010 - Issue 10
Submit an article Journal homepage
377
Views
19
CrossRef citations to date
0
Altmetric
Original Research

Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis

Masanori Abe Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, 30-1 Oyaguchi Kami-chou, Itabashi-ku, Tokyo 173-8610, Japan +81 3 3972 8111; +81 3 3972 1098; [email protected]
,
Kazuyoshi Okada Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, 30-1 Oyaguchi Kami-chou, Itabashi-ku, Tokyo 173-8610, Japan +81 3 3972 8111; +81 3 3972 1098; [email protected]
,
Takashi Maruyama Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, 30-1 Oyaguchi Kami-chou, Itabashi-ku, Tokyo 173-8610, Japan +81 3 3972 8111; +81 3 3972 1098; [email protected]
,
Noriaki Maruyama Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, 30-1 Oyaguchi Kami-chou, Itabashi-ku, Tokyo 173-8610, Japan +81 3 3972 8111; +81 3 3972 1098; [email protected]
,
Masayoshi Soma Division of General Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan
&
Koichi Matsumoto Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, 30-1 Oyaguchi Kami-chou, Itabashi-ku, Tokyo 173-8610, Japan +81 3 3972 8111; +81 3 3972 1098; [email protected]
Pages 1611-1620 | Published online: 14 Jun 2010

Bibliography

  • Ritz E, Rychlik I Locatelli F, Halimi S. End stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999;34:795-808
  • Wong TY, Szeto CC, Chow KM, Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. Am J Kidney Dis 2005;46:713-9
  • Campbell IW. The clinical significance of PPARgamma agonism. Curr Mol Med 2005;5:349-63
  • Shinohara K, Shoji T, Emoto M, Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002;13:1894-900
  • Martens FM, Visseren FL, Lemay J, Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002;62:1463-80
  • Lin SH, Lin YF, Kuo SW, Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CAPD. Am J Kid Dis 2003;42:774-80
  • Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int 2006;70:1223-33
  • Iglesias P, Diez JJ. Peroxisome proliferator-activated receptor gamma agonists in renal disease. Eur J Endocrinol 2006;154:613-21
  • Abe M, Kikuchi F, Kaizu K, Matsumoto K. Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis. Clin Nephrol 2007;68:287-94
  • Abe M, Okada K, Kikuchi F, Matsumoto K. Clinical investigation of the effects of pioglitazone on the improvement of insulin resistance and blood pressure in type 2 diabetic patients undergoing hemodialysis. Clin Nephrol 2008;70:220-8
  • Gejyo F, Saito A, Akizawa T, 2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients. Ther Apher Dial 2004;8:443-59
  • Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acutephase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999;33:63-72
  • Spaia S, Pangalos M, Askepidis N, Effect of short-term rHuEPO treatment on insulin resistance in haemodialysis patients. Nephron 2000;84:320-5
  • Mak RHK. Renal disease, insulin resistance and glucose intolerance. Diabetes Rev 1994;2:19-28
  • De Fronzo RA, Alvestrand A, Smith D, Insulin resistance in uremia. J Clin Invest 1981;67:563-8
  • Hager SR. Insulin resistance of uremia. Am J Kidney Dis 1989;14:272-6
  • Tuzcu A, Bahceci M, Yilmaz ME, The determination of insulin sensitivity in hemodialysis and continuous ambulatory peritoneal dialysis in nondiabetic patients with end-stage renal disease. Saudi Med J 2005;26:786-91
  • Barany P, Divino FJC, Bergstrome J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 1997;29:565-8
  • Sitter T, Berger A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 2000;15:1207-11
  • Kalantar ZK, McAllister C, Lehn R, Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 2003;42:761-73
  • Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998;18:555-9
  • Kalantar ZK, Ikizler A, Block G, Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 2003;42:864-81
  • Chiang CK, Ho TI, Peng YS, Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection. Diabetes Care 2007;30:3-7
  • Manley HJ, Allcock NM. Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. Pharmacotherapy 2003;23:861-5
  • Phillips LS, Grunberger G, Miller E, Once- and twice- daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001;24:308-15
  • Aronoff S, Rosenblatt S, Braithwaite S, Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. Diabetes Care 2000;23:1605-11
  • Wiecek A, Adamczak M, Chudek J. Adiponectin – an adipokine with unique metabolic properties. Nephrol Dial Transplant 2007;22:981-8

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.